China's Genscript Biotech hits 5-month low after posting yearly loss

Genscript Biotech

31/03/2023 05:33

** Shares of China's Genscript Biotech Corp  1548.HK  fall
as much as 7.3% to HK$16.66, their lowest since Oct. 18, 2022
    ** Stock on track for a second consecutive session of
decline; eighth-biggest pct loser in Hang Seng Composite Index
 .HSCI  
    ** Jiangsu-based biotech firm says its 2022 revenue up 27.7%
year-on-year to $625.7 mln, while its loss attributable to
owners of the company amounted to $226.9 mln as compared with
$358.7 mln loss in 2021 
    ** Co says it will expand its investment in research and
development to improve competitiveness of its products and
services
    ** Hang Seng Commerce & Industry Index  .HSNC  rises 1.5%,
while healthcare index  .HSCIH  falls 1.2%
    ** Hang Seng Composite Index  .HSCI  climbs 1.1% and Hang
Seng Index  .HSI  gains 0.8%
    ** As of last close, the stock had fallen 27.7% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))